Introduction Bilinguals with aphasia (BWA) present varying degrees of lexical access impairment and recovery across their two languages. Because both languages may benefit from therapy, identifying the optimal target language for treatment is a current challenge for research and clinical practice. Prior research has demonstrated that the BiLex computational model can accurately simulate lexical access in healthy bilinguals, and language impairment and treatment response in bilingual aphasia. Here, we aim to determine whether BiLex can predict treatment outcomes in BWA in the treated and the untreated language and compare these outcome predictions to determine the optimal language for rehabilitation. Methods and analysis The study involves a prospective parallel-group, double-blind, randomised controlled trial. Forty-eight Spanish–English BWA will receive 20 sessions of semantic treatment for lexical retrieval deficits in one of their languages and will complete assessments in both languages prior and after treatment. Participants will be randomly assigned to an experimental group receiving treatment in the optimal language determined by the model or a control group receiving treatment in the language opposite to the model’s recommendation. Primary treatment outcomes include naming probes while secondary treatment outcomes include tests tapping additional language domains. Treatment outcomes will be compared across the two groups using 2×2 mixed effect models for repeated measures Analysis of variance (ANOVA) on metrics of treatment effects commonly employed in rehabilitation studies (ie, effect size and percentage change). Ethics and dissemination All procedures included in this protocol (protocol number 29, issue date: 19 March 2019) were approved by the Boston University Charles River Campus Institutional Review Board at Boston, Massachusetts (reference number: 4492E). The results of this study will be published in peer-reviewed scientific journals and will be presented at national and international conferences. Trial registration number NCT02916524.
Apathy, depression, and anxiety are common non-motor symptoms of Parkinson’s disease (PD). Tracking the changes in such symptoms over time would be valuable not only to determine their natural course during the disease, but also to establish the effects of unusual historical events interacting with the natural course. Having collected data on apathy (Apathy Scale), depression (Beck Depression Inventory-II), and anxiety (Parkinson’s Anxiety Scale) in a large sample of persons with PD (PwPD) before the beginning of the COVID-19 era, we followed up with these individuals to investigate the changes in their prevalence of apathy, depression, and anxiety across two timepoints (T1 and T2). Of the original 347 participants, 111 responded and provided complete data at T2. The data collection at T1, before COVID-19, occurred between 2017–2018. The data collection at T2 occurred in 2021 and included the same measures, with the addition of the Coronavirus Impact Scale to assess the effects of the pandemic on the individual participants. Over this period, there was a significant increase in apathy, but not in depression or anxiety. Anxiety and depression, but not apathy, were correlated with the impact of COVID-19.
Background/Objectives: Social isolation and health-related consequences of the COVID-19 pandemic may have significantly impacted quality of life in people with Parkinson’s disease (PwPD). The effect of the COVID-19 pandemic specifically on subjective cognition and social functioning in PwPD is poorly understood. We conducted a longitudinal analysis of changes in subjective cognitive and social functioning in PwPD before (T1, 2017–2019) and during (T2, 2021) the COVID-19 pandemic. Methods: At T1, 347 PwPD completed online surveys. At T2, 123 of them (54 males, 69 females) responded to follow-up questionnaires including Quality of Life in Neurological Disorders (Neuro-QoL) subscales, Beck Depression Inventory-II, Parkinson’s Anxiety Scale, motor and non-motor experiences of daily living from the MDS-Unified Parkinson’s Disease Rating Scale, and the Coronavirus Impact Scale. Results: T1–T2 declines in subjective cognition and social functioning both were correlated with more anxiety, fatigue, and motor symptoms. Additionally, declines in subjective cognition correlated with depression, and with decline in social functioning. Women reported greater COVID-19 impact than men, unrelated to cognition and social functioning; in men, personal experience with COVID-19 was associated with decline in subjective cognition. Conclusions: Our finding that subjective cognition and social functioning are associated with different motor and non-motor symptoms of PD suggests that the impacts of PD on subjective cognition and social functioning are complex, which has important implications for treatment.
Subjective cognitive decline is common in persons with Parkinson's disease (PwPD) and prodromal PD (proPD) and predicts objective cognitive decline. Subjective concerns may reflect enhanced sensitivity to cognitive changes or negative global metacognitive biases (general underconfidence, not task specific) related to depression or anxiety. We evaluated the presence and predictors of metacognitive awareness, the self-assessment of one's cognitive abilities, in PwPD and proPD. Data from 468 PwPD, 817 proPD, and 75 healthy control adults were drawn from the Parkinson's Progressive Markers Initiative database. Measures included subjective- and objective-cognitive composites. We assessed metacognitive sensitivity (the relation between subjective and objective cognition) and the relation between metacognitive bias (subjective minus objective cognition) and depression, anxiety, demographics, and PD-related variables. Significant associations were included in linear regression models separately for PwPD and proPD. To assess effect consistency, we examined baseline versus Time 2 difference scores in a subsample who had the same measures 12 months later. ProPD (ρ = .13), but not PwPD (ρ = .08), showed significant metacognitive sensitivity. More negative metacognitive bias was predicted by age, education, depression, and trait anxiety in PwPD (R² = .17) and proPD (R² = .24). The relation between anxiety and negative metacognitive bias was consistent over a 12-month period for PwPD (ρ = -.18; R² = .05). Negative metacognitive bias, predicted by depression and anxiety, may underlie subjective cognitive concerns in PwPD and proPD, with implications for treatment. These findings support using global approaches to metacognitive awareness, which are likely more accurate measures of daily cognitive awareness than are task-specific measures. (PsycInfo Database Record (c) 2026 APA, all rights reserved).